U.S. Patent 2,656,508. This is the patent number for the first impedance-based flow cytometry device, using the Coulter principle issued in 1953, to Wallace H. Coulter. Mack Fulwyler was the inventor of the forerunner to today’s flow cytometers – particularly the cell sorter. In November 1965, Fulwyler introduced to the world in his Science publication a device capable of separating biological cells suspended in a conducting medium according to volume. With over 80 years of technological innovation, flow cytometers continue to decrease in size and energy consumption and increase in detection and precision measurements. It is not uncommon in today’s daily research to see high-throughput single-cell technologies included in experimental methods. The progression in the number of different molecules that can be measured in a single cell has completely changed the way experiments are done and analyzed.
Consider the printing press. US Patent US1970368A, the printing press changed the world allowing for the mass production of uniform printed matter, mainly text in the form of books, pamphlets and newspapers. Originally created in China, the printing press developed in Europe in the 15th Century by Johannes Gutenberg, not only altered the way the world shared opinions in prose, but significantly revolutionized the sharing of scientific knowledge. As a weekly scientific journal publication, Nature has been featuring peer-reviewed research from a variety of academic disciplines, mainly in science, technology, and the natural sciences since its first publication November 1869. Imagine the negative impact of the millions of written discoveries like the works of Sir Isaac Newton (1687), Radium and Radioactivity by Marie Curie (1904), William Harvey’s (1628) Exercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus, the account of the blood circulation, never being circulated.
Advanced high-throughput flow cytometry has completely changed the landscape of how clinicians determine effective therapeutics to patients diagnosed with hematological cancer.
Notable Lab’s advanced high-throughput flow cytometry enables the collection of >20 dimensions of data at the single cell level. The way the printing press took one written prose and impacted millions of readers, imagine a single patient sample divided into 100 to 1000s of experimental conditions resulting in over 100,000 data points from each test condition, one data point providing a possible cure. The patient impact is inconceivable. Notable Labs ex vivo DSS functional platform is a novel precision medicine approach used to identify rational drugs and drug combinations and predict clinical therapeutic responses in patients with relative high accuracy in the range of 80-85%. Notable Labs has revolutionized the precision medicine approach.
By testing very large numbers of experimental conditions through automation from a single sample saves time and money without compromising quality. Pooling results from multiple samples has its disadvantages. There is increased variability from technician sampling and storage conditions to human error running the assay or assays. The Notable Labs automation workflow allows hundreds of miniaturized experiments from one sample to be performed with limited human involvement and a high degree of precision. This powerful platform provides clinicians efficacious therapeutic options to treat their patients in a timely (7-10 days) and accurate manner. To learn more about Notable Labs mission visit us at www.notablelabs.com.